Novel neuromuscular blocking drugs and antagonists
暂无分享,去创建一个
[1] R. Urman,et al. Novel drug development for neuromuscular blockade , 2016, Journal of Anaesthesiology Clinical Pharmacology.
[2] T. Ledowski. Sugammadex: What do we Know and What do we Still Need to Know? A Review of the Recent (2013 to 2014) Literature , 2015, Anaesthesia and intensive care.
[3] Ingrid Moreno-Duarte,et al. Residual Paralysis: Does it Influence Outcome After Ambulatory Surgery? , 2014, Current Anesthesiology Reports.
[4] Jian Ji,et al. pH responsive supramolecular prodrug micelles based on cucurbit[8]uril for intracellular drug delivery. , 2014, Chemical communications.
[5] Lyle Isaacs,et al. Stimuli Responsive Systems Constructed Using Cucurbit[n]uril-Type Molecular Containers , 2014, Accounts of chemical research.
[6] P. Heerdt,et al. Comparative pharmacodynamics of pancuronium, cisatracurium, and CW002 in rabbits. , 2014, Journal of the American Association for Laboratory Animal Science : JAALAS.
[7] T. Schepens,et al. Neuromuscular blockade: what was, is and will be. , 2014, Acta anaesthesiologica Belgica.
[8] D. Macartney. Cucurbit[n]uril type hosts for the reversal of steroidal neuromuscular blocking agents. , 2013, Future medicinal chemistry.
[9] C. Ayata,et al. Calabadion: A New Agent to Reverse the Effects of Benzylisoquinoline and Steroidal Neuromuscular-blocking Agents , 2013, Anesthesiology.
[10] Matthias Eikermann,et al. Acyclic cucurbit[n]uril-type molecular containers bind neuromuscular blocking agents in vitro and reverse neuromuscular block in vivo. , 2012, Angewandte Chemie.
[11] C. Lien. Development and potential clinical impairment of ultra-short-acting neuromuscular blocking agents. , 2011, British journal of anaesthesia.
[12] H. Sunaga,et al. Rapid Chemical Antagonism of Neuromuscular Blockade by l-Cysteine Adduction to and Inactivation of the Olefinic (Double-bonded) Isoquinolinium Diester Compounds Gantacurium (AV430A), CW 002, and CW 011 , 2010, Anesthesiology.
[13] Edward J Yoon,et al. Cysteine Reversal of the Novel Neuromuscular Blocking Drug CW002 in Dogs: Pharmacodynamics, Acute Cardiovascular Effects, and Preliminary Toxicology , 2010, Anesthesiology.
[14] F. Chung,et al. Hypothermia For Neuroprotection In Adults After Cardiopulmonary Resuscitation , 2010, The Cochrane database of systematic reviews.
[15] H. Sunaga,et al. Pharmacodynamics and Cardiopulmonary Side Effects of CW002, a Cysteine-reversible Neuromuscular Blocking Drug in Dogs , 2010, Anesthesiology.
[16] H. Sunaga,et al. Gantacurium and CW002 Do Not Potentiate Muscarinic Receptor-mediated Airway Smooth Muscle Constriction in Guinea Pigs , 2010, Anesthesiology.
[17] M. Berk,et al. Oxidative Stress in Psychiatric Disorders: Evidence Base and Therapeutic Implications , 2009 .
[18] Chingmuh Lee,et al. The development of ultrashort acting neuromuscular relaxant tropane derivatives. , 2009, Journal of critical care.
[19] C. Lien,et al. Fumarates: unique nondepolarizing neuromuscular blocking agents that are antagonized by cysteine. , 2009, Journal of critical care.
[20] J. Lépine,et al. New treatments for cocaine dependence: a focused review. , 2008, The international journal of neuropsychopharmacology.
[21] P. Cheeseman,et al. Safety and efficacy of N‐acetylcysteine in children with non‐acetaminophen‐induced acute liver failure , 2008, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.
[22] M. Wolzt,et al. Effects of N-acetylcysteine against systemic and renal hemodynamic effects of endotoxin in healthy humans , 2007, Critical care medicine.
[23] L. Gyermek. Development of ultra short‐acting muscle relaxant agents: History, research strategies, and challenges , 2005, Medicinal research reviews.
[24] A. Scarda,et al. High-Dose N-Acetylcysteine in Patients with Exacerbations of Chronic Obstructive Pulmonary Disease , 2005, Clinical drug investigation.
[25] O. Sawamoto,et al. L-cysteine-induced brain damage in adult rats. , 2004, Experimental and toxicologic pathology : official journal of the Gesellschaft fur Toxikologische Pathologie.
[26] Sanjay S. Patel,et al. Preclinical Pharmacology of GW280430A (AV430A) in the Rhesus Monkey and in the Cat: A Comparison with Mivacurium , 2004, Anesthesiology.
[27] Sanjay S. Patel,et al. Clinical Pharmacology of GW280430A in Humans , 2004, Anesthesiology.
[28] P. Heerdt,et al. Cardiopulmonary Effects of the Novel Neuromuscular Blocking Drug GW280430A (AV430A) in Dogs , 2004, Anesthesiology.
[29] S. Oja,et al. Mechanisms of L-Cysteine Neurotoxicity , 2000, Neurochemical Research.
[30] Sanjay S. Patel,et al. Neuromuscular blocking activity and therapeutic potential of mixed-tetrahydroisoquinolinium halofumarates and halosuccinates in rhesus monkeys. , 2003, Journal of medicinal chemistry.
[31] A. Bom,et al. Cyclodextrin-derived host molecules as reversal agents for the neuromuscular blocker rocuronium bromide: synthesis and structure-activity relationships. , 2002, Journal of medicinal chemistry.
[32] P. White. Rapacuronium: why did it fail as a replacement for succinylcholine? , 2002, British journal of anaesthesia.
[33] C. Meistelman. Update on neuromuscular pharmacology , 2001, Current opinion in anaesthesiology.
[34] J. A. Ray,et al. Stereocontrolled synthesis of cis-dibenzoquinolizine chlorofumarates: curare-like agents of ultrashort duration. , 2001, The Journal of organic chemistry.
[35] J. A. Ray,et al. Synthesis of ultra-short-acting neuromuscular blocker GW 0430: a remarkably stereo- and regioselective synthesis of mixed tetrahydroisoquinolinium chlorofumarates. , 1999, Organic letters.
[36] J. A. Ray,et al. Bis- and mixed-tetrahydroisoquinolinium chlorofumarates: new ultra-short-acting nondepolarizing neuromuscular blockers. , 1999, Journal of medicinal chemistry.
[37] Boswell,et al. Bis- and mixed-tetrahydroisoquinolinium chlorofumarates: new ultra-short-acting nondepolarizing neuromuscular blockers , 1999, Journal of medicinal chemistry.
[38] R. Marshall,et al. Research and development of aminosteroid neuromuscular blocking agents: past and future. , 1995, European journal of anaesthesiology. Supplement.
[39] C. Lien,et al. The clinical and basic pharmacology of mivacurium: a short‐acting nondepolarizing benzylisoquinolinium diester neuromuscular blocking drug , 1995, Acta anaesthesiologica Scandinavica. Supplementum.
[40] R. Rodríguez-Roisín. Pulmonary gas exchange in acute respiratory failure. , 1994, European journal of anaesthesiology.
[41] M. H. Bryan,et al. Cysteine supplementation to cysteine-free intravenous feeding regimens in newborn infants. , 1981, The American journal of clinical nutrition.
[42] J. Olney,et al. Brain damage and associated behavioral deficits following the administration of L-cysteine to infant rats , 1975, Pharmacology Biochemistry and Behavior.